Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.02 – $0.23
71% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.8M | $4.4M | $2.2M | $11.4M | $19.6M | $26.1M | $21.8M | $11.6M |
| Cost of revenue | $4.8M | $5.6M | $5.8M | $6.9M | $10.0M | $12.6M | $7.6M | $12.6M |
| Gross profit | −$973.0K | −$1.2M | −$3.7M | $4.6M | $9.6M | $13.5M | $21.8M | −$945.4K |
| Gross margin | -25.5% | -27.9% | -171.4% | 39.9% | 49.0% | 51.7% | 100.0% | -8.1% |
| R&D | $1.8M | $3.9M | $4.6M | $5.1M | $8.5M | $13.2M | $14.6M | $13.6M |
| Operating income | −$19.2M | −$19.8M | −$22.6M | −$22.2M | −$34.4M | −$45.9M | −$34.1M | −$38.2M |
| EBITDA | −$19.0M | −$18.4M | −$15.4M | −$21.8M | −$32.8M | −$32.3M | −$31.8M | −$35.6M |
| Net income | −$17.9M | −$18.9M | −$14.2M | −$19.8M | −$27.0M | −$29.5M | −$29.9M | −$36.1M |
| Net margin | -469.4% | -432.2% | -660.9% | -172.9% | -137.5% | -113.3% | -137.0% | -311.1% |
| EPS (diluted) | -0.03 | -0.03 | -0.02 | -0.03 | -0.03 | -0.04 | -0.04 | -0.04 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $19M | $-0.03 | $-0.03–$-0.03 | 1 |
| 2028 | $36M | $-0.02 | $-0.02–$-0.02 | 1 |
| 2029 | $59M | $-0.00 | $-0.00–$-0.00 | 1 |
Forward consensus · source: Financial Modeling Prep
PACIFIC EDGE LTD ORD
No one on the platform currently holds PFGTF.
No tracked institution reports a position in PFGTF as of their last filing.
No one on the platform has traded PFGTF yet.
| -10.20% |
| $57M |
| — |
| SHIEFShield Therapeutics plc | $0.08 | +0.00% | $86M | — |
| SNZZFSenzime AB (publ) | $0.48 | +0.00% | $75M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 3.2× sales vs its 6.1× historical median P/S.
Fair value ≈ $0.33 · price $0.17 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.